We hope our study contributes to the efforts of finding new drug targets and agents for metabolic diseases, including type 2 diabetes, and recommends Sirt3 activators as potential agents in the treatment of insulin resistance and other metabolic abnormalities. The gene discussed is SIRT3; the disease is Insulin resistance.